scholarly journals Use of nanotechnology for infectious disease diagnostics: application in drug resistant tuberculosis

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Roshanthi Eranga Karunaratne ◽  
Lahiru A. Wijenayaka ◽  
Sandya Sulochana Wijesundera ◽  
K. M. Nalin De Silva ◽  
Chamila Priyangani Adikaram ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Disease Diagnostics ◽  
Infectious Disease Diagnostics

scholarly journals MDRTB Then, XMDRTB Now and Then ……… Totally

JMS SKIMS ◽  
2016 ◽  
Vol 19 (1) ◽  
pp. 12-17
Author(s):  
Ajaz Nabi Koul
Keyword(s):  
Infectious Disease ◽  
Considerable Increase ◽  
Significant Proportion ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis ◽  
Health Related ◽  
Sporadic Cases ◽  
Area Of Concern

Multi drug resistant tuberculosis has come up as a separate disease meriting different diagnostic and therapeutic options from conventional tuberculosis. Worldwide there has been considerable increase in MDRTB cases to 60,000 and less than 5% of them get management as desired by various infectious disease bodies. Another entity titled XMDRTB has of late assumed significant proportion of tuberculosis cases which is steaming into a new health related inferno. Some sporadic cases of tuberculosis have come up which are completely resistant to all anti-tubercular drugs, that should be an area of concern for all healthcare givers. JMS 2016; 19(1):12-17

scholarly journals Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis

Folia Medica ◽  
2020 ◽  
Vol 62 (3) ◽  
pp. 444-452
Author(s):  
Dionysia D. Fermeli ◽  
Theodoros D. Marantos ◽  
Alexandros-Leonidas D. Liarakos ◽  
George D. Panayiotakopoulos ◽  
Vasileios K. Dedes ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Adverse Effects ◽  
Cost Benefit ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant ◽  
Promising Agent ◽  
Ribosomal Protein Synthesis ◽  
The Cost

Tuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis. The aim of this review was to present the efficacy of linezolid as an agent against multidrug and extensively drug-resistant tuberculosis as gathered from many recent research studies. Linezolid seems to have strongly the potential of being used as an anti-tuberculosis agent because it blocks bacterial ribosomal protein synthesis. Nevertheless caution is required because of the adverse effects it causes, especially when the linezolid daily dosage exceeds 600 mg. The most severe adverse effects include anemia, peripheral neuropathy, optic neuropathy and thrombocytopenia. Still, more trials and research need to be done in order to gather more information and value the cost-benefit dosage of the treatment. 

Sign in / Sign up

Export Citation Format

Share Document